SUMMARY: Studies have shown that linezolid achieves good clinical outcomes against multidrugresistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). However, the efficacy of linezolid for individual TB patients and its precise contribution to combination regimens remain unclear for Chinese patients. This study examined the clinical outcomes and safety of linezolid in adults with XDR pulmonary TB at the Chinese PLA 309 hospital. Sixteen XDR-TB patients received linezolid (600 mg daily) in addition to vitamin B6 (50-100 mg daily) as part of their individualized treatment regimens. Of the 16 patients, 14 had received previous treatment for tuberculosis. Sputum samples for all patients showed high colony-forming unit counts when tested by a real-time polymerase chain reaction (PCR). In addition, a high proportion of patients had cavitary lesions in the lungs. Eleven of the 16 patients (68.75z) had successfully completed therapy with documented negative quantitative PCR (qPCR) data and cultures at follow-up (mean ＝ 12 months). Three patients (18.75z) are still receiving treatment, and all 3 have shown clinical and radiographic improvement. Linezolid was discontinued for 2 patients with persistent positive qPCR data and cultures because they developed severe, intractable diarrhea and nausea shortly after beginning treatment. Data indicated that linezolid was a well-tolerated and efficient treatment for XDB-TB in of Chinese patients.
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The recent increase in multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is an international public health threat. More than 90 countries have reported MDR-TB cases, and XDR-TB has been found in more than 60 countries. Especially high rates have been documented in India, Russia, South Africa, and some areas of the People's Republic of China (1) . China has the second-largest number of TB cases in the world, and drug resistance is a serious public health issue due to the excessive use of second-line drugs. Therefore, new chemotherapeutic regimens are urgently needed to treat MDR-TB and XDR-TB cases in Chaina.
Linezolid, the first oxazolidinone antibacterial agent that was approved for clinical use, has shown good clinical outcomes against TB in some studies, regardless of drug resistant patterns (2-4). However, its efficacy in individual TB patients and its precise contribution to combination regimens remain unclear in Chinese patients. Considering that the clinical efficacy of the antibiotic varied across geographical region, investigations that describe the clinical use of linezolid in China should be performed to explore whether linezolid may be effective in treating MDR-and XDR-TB in Chinese patients. In this study, we examined the clinical outcomes and safety of linezolid in adults with XDR pulmonary TB in the Chinese PLA 309 hospital, the Chinese military's center for tuberculosis treatment and research.
Patients in this study (n ＝ 16) were recruited by the Chinese PLA 309 hospital between January 2011 and December 2013. Background information for each patient (e.g., name, age, gender, birthplace, and medical treatment history) was recorded by their attending physicians when the patients were first hospitalized. None of the patients were HIV-infected. Those with delayed puberty were excluded from the study. Standard smears for acid-fast bacilli were performed with Ziehl-Neelsen staining, and mycobacterial cultures were conducted using Lowenstein-Jensen media. Phenotypic drug resistance was determined using Middlebrook 7H10 agar media supplemented with oleic acid, albumin, dextrose, and catalase. All patients were treated with linezolid and at least 3 other second-line companion drugs selected according to their individual drug history and recent susceptibility results. All patients received oral linezolid at a dosage of 600 mg daily. Treatment regimens also included vitamin B6 at a dosage of 50-100 mg daily to reduce the risk of hematologic toxicity.
At least 3 sputum samples were collected from each patient prior to and during the treatment period. Sputum samples were placed into 50 ml screw-cap centrifuge tubes and sent daily from the ward to the microbiology laboratory where the specimens were stored at 49 C until they could be processed. Colonyforming unit (CFU) counts were determined by a realtime polymerase chain reaction (PCR) assay [(Mycobacterium Tuberculosis Real Time PCR Kit (Liferiver Company, China)] and mycobacterial cultures as described in previous reports (5, 6) . CFU counts were conducted every week until negative results were found con- Efficacy of Linezolid against XDR-TB secutively for at least one month. A complete blood count, urinalysis, and serum aspartate aminotransferase were reviewed weekly to monitor for adverse events. And total bilirubin, creatinine, and glucose levels were similarly reviewed weekly. Sixteen XDR patients (10 male; 6 female) between the ages of 19 and 60 years old with a body weight range of 45.5 to 82.5 kg were treated with linezolid. Of the 16 patients, 14 had a history of tuberculosis treatment. Sputum samples for all patients showed high CFU counts when tested by a real-time PCR, and there was a high proportion of patients with cavitary lesions in the lungs (n ＝ 12; 75z). Table 1 shows the specific drugs used in each case. The median number of drugs used for these patients was 5. Drugs were chosen according to the drug susceptibility test results. Isoniazid, rifampicin, and ofloxacin were not used because all 16 XDR-TB cases showed resistant to these drugs. The mean duration of linezolid administration was 9.53 months (range 3-21 months).
As shown in Table 2 , 11 of the 16 patients (68.75z) successfully completed therapy with documented negative qPCR data and cultures at folow up (mean followup 12 months; range 4-18 months). 3 patients (18.75z) are still receiving treatment; however, all 3 have shown clinical and radiographic improvement. The median time to qPCR or culture conversion among the 14 achieved conversion cases was 7.86 weeks. None of the 11 patients who successfully completed treatment, relapsed at follow-up.
Gastrointestinal adverse events occurred in 5 of the 16 patients. Linezolid use was suspended in 2 patients with persistent positive qPCR data or cultures because both of them developed severe, intractable diarrhea and nausea shortly after beginning linezolid. These cases were defined as treatment failure cases (12.5z). Hematological adverse events occurred in 6 patients. Four patients experienced mild-to-moderate anemia, and 2 patients developed mild thrombocytopenia. However, none of these patients stopped the linezolid treatment. Peripheral neuropathy occurred in 3 patients; however, all 3 continued the linezolid treatment under careful monitoring. Lactic acidosis and serotonin syndrome, known side effects of linezolid (7, 8) , were not seen in our study.
Over the past 20 years, the TB morbidity rate has been declining worldwide. However, the disease is still considered one of the most fatal infectious diseases in developing countries (9) . The XDR-TB patterns identified in a 2006 report (10) , indicated that the pathogenic bacterium is susceptible to fewer than 3 classes of second-line drugs. This makes it difficult for treatment to meet international standards. In addition, patients with XDR-TB have a higher risk of death and treatment failure than those with MDR-TB. The northern and northeastern regions of China are adjacent to Russia and Mongolia, two countries with a high rate of XDR-TB (11, 12) . Given that Beijing, the political and financial center of China, is located in northern region of China, a high likelihood of XDR-TB transmission is possible. Therefore, new drug candidates should be recommended to recruit the anti-TB drug catalogue in this area.
Published clinical trials have demonstrated the efficacy of linezolid as part of an optimized MDR-TB or XDR-TB regimen; however several studies have also reported its inefficacy and side effect induced failures. For example, Lee et al. (4) reported that by 16 weeks, 63z of patients (n ＝ 12/19) being treated with a linezolid containing regimen showed culture conversion in liquid medium and several clinically significant adverse events (e.g., myelosuppression, peripheral neuropathy, optic neuropathy, hepatic enzyme elevation, and rhabdomyolysis). Park et al. (13) reported successful culture conversion in 8 HIV-negative patients; however, even with a daily linezolid dose of 600 mg, the study described a high incidence of side effects indicating that linezolid may be effective but is poorly tolerat- (3) . In this study, all patients received vitamin B6 as part of their treatment regimen. Although 6 patients experienced mild-tomoderate anemia and thrombocytopenia, no patients terminated the linezolid treatment because of myelosuppression.
The small sample size in this study limits its generalizability. Furthermore, although the results are encouraging and few treatment failures and cases of acquired resistance were reported, we cannot conclude that linezolid is suitable for all XDR-TB patients in China. Although we recommend the use of linezolid, patients must be closely monitored for any adverse side effects. Furthermore, linezolid TB treatment guidelines are necessary.
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